Y-mAbs Therapeutics (YMAB) News Today $4.52 -0.18 (-3.83%) As of 03:04 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock YMAB Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 Time Period YMAB Y-mAbs Therapeutics, Inc. - Seeking AlphaJune 28 at 3:47 PM | seekingalpha.comY mAbs Therapeutics News (YMAB) - Investing.comJune 26, 2025 | investing.comWe're Not Very Worried About Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn RateJune 11, 2025 | finance.yahoo.comWesbanco Bank Inc. Acquires Shares of 55,000 Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)June 11, 2025 | marketbeat.comCantor Fitzgerald Comments on YMAB FY2026 EarningsJune 10, 2025 | marketbeat.comY-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Receives Consensus Rating of "Moderate Buy" from AnalystsJune 9, 2025 | marketbeat.comY-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Shares Acquired by Bank of America Corp DEJune 8, 2025 | marketbeat.comY-mAbs Therapeutics (NASDAQ:YMAB) Price Target Lowered to $15.00 at OppenheimerMay 30, 2025 | marketbeat.comWedbush Reiterates Outperform Rating for Y-mAbs Therapeutics (NASDAQ:YMAB)May 29, 2025 | marketbeat.comWedbush Reaffirms "Outperform" Rating for Y-mAbs Therapeutics (NASDAQ:YMAB)May 29, 2025 | marketbeat.comY-mAbs Hosts Virtual Radiopharmaceutical R&D Update Highlighting Clinical Progress and Expanded PipelineMay 28, 2025 | globenewswire.comInfinitum Asset Management LLC Purchases New Stake in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)May 28, 2025 | marketbeat.comY-mAbs Therapeutics, Inc. (YMAB) Unveils Promising Cancer Trial Data at ANR 2025May 26, 2025 | insidermonkey.comY-mAbs Presents GD2-SADA PRIT Trial in Progress Poster at the Advances in Neuroblastoma Research MeetingMay 26, 2025 | globenewswire.comY-mAbs Therapeutics’ SWOT analysis: antibody innovator’s stock faces growth hurdlesMay 24, 2025 | investing.comHC Wainwright Brokers Decrease Earnings Estimates for YMABMay 23, 2025 | marketbeat.comFY2026 Earnings Forecast for YMAB Issued By HC WainwrightMay 22, 2025 | marketbeat.comY-mAbs Therapeutics (NASDAQ:YMAB) Price Target Cut to $11.00 by Analysts at HC WainwrightMay 21, 2025 | marketbeat.comD. E. Shaw & Co. Inc. Has $4.82 Million Stake in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)May 20, 2025 | marketbeat.comWedbush Cuts Earnings Estimates for Y-mAbs TherapeuticsMay 17, 2025 | marketbeat.comY-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Receives Average Rating of "Moderate Buy" from BrokeragesMay 17, 2025 | marketbeat.comTruist Financial Sticks to Its Buy Rating for Y-Mabs Therapeutics (YMAB)May 16, 2025 | theglobeandmail.comParadigm Biocapital Advisors LP Grows Holdings in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)May 16, 2025 | marketbeat.comY-mAbs Therapeutics Inc (YMAB) Q1 2025 Earnings Call Highlights: Navigating Growth and ChallengesMay 14, 2025 | finance.yahoo.comY-mAbs Therapeutics, Inc.: Y-mAbs Reports First Quarter 2025 Financial Results and Recent Corporate DevelopmentsMay 13, 2025 | finanznachrichten.deY-mAbs Therapeutics, Inc. (YMAB) Q1 2025 Earnings Call TranscriptMay 13, 2025 | seekingalpha.comY-mAbs to Host Virtual Radiopharmaceutical R&D Update on May 28, 2025May 13, 2025 | globenewswire.comY-mAbs Reports First Quarter 2025 Financial Results and Recent Corporate DevelopmentsMay 13, 2025 | globenewswire.comY-mAbs Announces Update to National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for Neuroblastoma to Include Naxitamab-gqgk (DANYELZA®)May 7, 2025 | globenewswire.comY-mAbs to Announce First Quarter 2025 Financial and Operating Results on May 13, 2025May 6, 2025 | globenewswire.comShort Interest in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Drops By 16.1%May 5, 2025 | marketbeat.com2,861,825 Shares in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Acquired by Acorn Capital Advisors LLCMay 4, 2025 | marketbeat.comCaligan Partners LP Has $13.84 Million Stock Position in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)May 3, 2025 | marketbeat.comRenaissance Technologies LLC Raises Position in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)May 3, 2025 | marketbeat.comY-mAbs Therapeutics (YMAB) Projected to Post Earnings on TuesdayMay 1, 2025 | marketbeat.comJPMorgan Chase & Co. Raises Stock Holdings in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)April 30, 2025 | marketbeat.comBoothbay Fund Management LLC Buys 136,264 Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)April 29, 2025 | marketbeat.comY-mAbs Therapeutics announces presentation of PK data of CD38-SADAApril 27, 2025 | markets.businessinsider.comY-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) latest 13% decline adds to one-year losses, institutional investors may consider drastic measuresApril 27, 2025 | finance.yahoo.comY-mAbs Presents Translational Pharmacokinetics of CD38-SADA from Pretargeted RIT Platform at 2025 American Association for Cancer Research (AACR) Annual MeetingApril 27, 2025 | globenewswire.comBrookline Capital Management Weighs in on YMAB Q1 EarningsApril 27, 2025 | marketbeat.comY-mAbs announces first patient dosed in Phase 1 trial of CD38-SADA PRIT platformApril 26, 2025 | markets.businessinsider.comY-mAbs Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating CD38-SADA Pre-targeted Radioimmunotherapy in Relapsed/Refractory Non-Hodgkin LymphomaApril 25, 2025 | globenewswire.comY-mAbs Therapeutics (NASDAQ:YMAB) Downgraded to "Underperform" Rating by Bank of AmericaApril 24, 2025 | marketbeat.comY-mAbs Therapeutics downgraded to Underperform from Neutral at BofAApril 23, 2025 | markets.businessinsider.comY-mAbs downgraded to Underperform at BofA on tough near-term setupApril 23, 2025 | markets.businessinsider.comY-mAbs drops as Bank of America downgrades on headwinds to DanyelzaApril 23, 2025 | msn.comY-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Receives Consensus Recommendation of "Moderate Buy" from AnalystsApril 21, 2025 | marketbeat.comY-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Short Interest UpdateApril 21, 2025 | marketbeat.comY-mAbs Therapeutics, Inc.April 16, 2025 | cnn.com Get Y-mAbs Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for YMAB and its competitors with MarketBeat's FREE daily newsletter. Email Address YMAB Media Mentions By Week YMAB Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. YMAB News Sentiment▼0.620.90▲Average Medical News Sentiment YMAB News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. YMAB Articles This Week▼34▲YMAB Articles Average Week Get Y-mAbs Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for YMAB and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ORIC News Today PRAX News Today COGT News Today CMRX News Today CDMO News Today AVXL News Today SNDX News Today AVBP News Today QURE News Today IMNM News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:YMAB) was last updated on 6/30/2025 by MarketBeat.com Staff From Our PartnersCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredGold prediction: $5,000/oz. or higher is comingThe perfect gold play right now? (currently under $10) Everything in the news now lines up perfectly for an...Stansberry Research | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredA grave, grave error.Famed financial analyst, Porter Stansberry, calls this technology “The Final Frontier” because it holds the ke...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Y-mAbs Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Y-mAbs Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free YMAB Stock Alerts